Gastrointestinal disorders as immune-related adverse events

Immune checkpoint inhibitors, such as cytotoxic T-lymphocyte antigen 4 inhibitors, programmed cell death 1 inhibitors and programmed cell death-ligand 1 inhibitors, have recently emerged as novel drugs in the anti-cancer therapy. Their use in different types of advanced cancer has shown good results...

Descripción completa

Detalles Bibliográficos
Autores principales: Balducci, Daniele, Quatraccioni, Claudia, Benedetti, Antonio, Marzioni, Marco, Maroni, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Open Exploration 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400751/
https://www.ncbi.nlm.nih.gov/pubmed/36046145
http://dx.doi.org/10.37349/etat.2021.00039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400751/
https://www.ncbi.nlm.nih.gov/pubmed/36046145
http://dx.doi.org/10.37349/etat.2021.00039

Ejemplares similares